Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea

Douglas M. Simon, John P. Cello, Jorge Valenzuela, Richard Levy, Gordon Dickerson, Richard Goodgame, Michael Brown, Kip Lyche, W. Jeffrey Fessel, James Grendell, C. Mel Wilcox, Nezam Afdhal, Ronald Fogel, Vonda Reeves-Darby, John Stern, Owen Smith, Frank Graziano, Douglas Pleakow, Timothy Flanigan, Timothy Schubert & 5 others Mark Loveless, Larry Eron, Paul Basuk, Maurizio Bonacini, Jan Orenstein

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Background/Aims: Diarrhea is a significant problem in patients with acquired immunodeficiency syndrome (AIDS). The aim of this study was to determine octreotide effectiveness in refractory AIDS-associated diarrhea. Methods: In a 3-week protocol, 129 patients with a stool weight of >500 g/day despite standard antidiarrheal therapy were randomized to receive octreotide or placebo (3:2 ratio). Octreotide dose was increased 100 μg weekly to a maximum of 300 μg three times a day based on weekly 72-hour stool collections. Subsequently, patients received open-label octreotide at doses of up to 500 μg three times a day. Results: A 30% decrease in stool weight defined response. After 3 weeks, 48% of octreotide- and 39% of placebo-treated patients had responded (P = 0.43). At 300 μg three times a day, 50% of octreotide- and 30.1% of placebo-treated patients responded (P = 0.12). At a baseline stool weight of 1000-2000 g/day, 57% of octreotide- and 25% of placebo-treated patients responded (P = 0.06). Response rates based on CD4 counts, diarrhea duration, body weight, human immunodeficiency virus risk factor, and presence or absence of pathogens showed no benefit of octreotide. Adverse events were more frequent in the octreotide-treated group. Conclusion: In the doses studied, octreotide was not more effective than placebo in patients with refractory AIDS-associated diarrhea. This lack of effectiveness may be attributable to inadequate sample size, doses, and duration of study treatment.

Original languageEnglish (US)
Pages (from-to)1753-1760
Number of pages8
JournalGastroenterology
Volume108
Issue number6
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Octreotide
Multicenter Studies
Diarrhea
Acquired Immunodeficiency Syndrome
Placebos
Weights and Measures
Antidiarrheals
CD4 Lymphocyte Count
Sample Size
Body Weight
HIV

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Simon, D. M., Cello, J. P., Valenzuela, J., Levy, R., Dickerson, G., Goodgame, R., ... Orenstein, J. (1995). Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea. Gastroenterology, 108(6), 1753-1760. https://doi.org/10.1016/0016-5085(95)90137-X

Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea. / Simon, Douglas M.; Cello, John P.; Valenzuela, Jorge; Levy, Richard; Dickerson, Gordon; Goodgame, Richard; Brown, Michael; Lyche, Kip; Fessel, W. Jeffrey; Grendell, James; Wilcox, C. Mel; Afdhal, Nezam; Fogel, Ronald; Reeves-Darby, Vonda; Stern, John; Smith, Owen; Graziano, Frank; Pleakow, Douglas; Flanigan, Timothy; Schubert, Timothy; Loveless, Mark; Eron, Larry; Basuk, Paul; Bonacini, Maurizio; Orenstein, Jan.

In: Gastroenterology, Vol. 108, No. 6, 1995, p. 1753-1760.

Research output: Contribution to journalArticle

Simon, DM, Cello, JP, Valenzuela, J, Levy, R, Dickerson, G, Goodgame, R, Brown, M, Lyche, K, Fessel, WJ, Grendell, J, Wilcox, CM, Afdhal, N, Fogel, R, Reeves-Darby, V, Stern, J, Smith, O, Graziano, F, Pleakow, D, Flanigan, T, Schubert, T, Loveless, M, Eron, L, Basuk, P, Bonacini, M & Orenstein, J 1995, 'Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea', Gastroenterology, vol. 108, no. 6, pp. 1753-1760. https://doi.org/10.1016/0016-5085(95)90137-X
Simon, Douglas M. ; Cello, John P. ; Valenzuela, Jorge ; Levy, Richard ; Dickerson, Gordon ; Goodgame, Richard ; Brown, Michael ; Lyche, Kip ; Fessel, W. Jeffrey ; Grendell, James ; Wilcox, C. Mel ; Afdhal, Nezam ; Fogel, Ronald ; Reeves-Darby, Vonda ; Stern, John ; Smith, Owen ; Graziano, Frank ; Pleakow, Douglas ; Flanigan, Timothy ; Schubert, Timothy ; Loveless, Mark ; Eron, Larry ; Basuk, Paul ; Bonacini, Maurizio ; Orenstein, Jan. / Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea. In: Gastroenterology. 1995 ; Vol. 108, No. 6. pp. 1753-1760.
@article{293012351cec496a94a531be0570652b,
title = "Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea",
abstract = "Background/Aims: Diarrhea is a significant problem in patients with acquired immunodeficiency syndrome (AIDS). The aim of this study was to determine octreotide effectiveness in refractory AIDS-associated diarrhea. Methods: In a 3-week protocol, 129 patients with a stool weight of >500 g/day despite standard antidiarrheal therapy were randomized to receive octreotide or placebo (3:2 ratio). Octreotide dose was increased 100 μg weekly to a maximum of 300 μg three times a day based on weekly 72-hour stool collections. Subsequently, patients received open-label octreotide at doses of up to 500 μg three times a day. Results: A 30{\%} decrease in stool weight defined response. After 3 weeks, 48{\%} of octreotide- and 39{\%} of placebo-treated patients had responded (P = 0.43). At 300 μg three times a day, 50{\%} of octreotide- and 30.1{\%} of placebo-treated patients responded (P = 0.12). At a baseline stool weight of 1000-2000 g/day, 57{\%} of octreotide- and 25{\%} of placebo-treated patients responded (P = 0.06). Response rates based on CD4 counts, diarrhea duration, body weight, human immunodeficiency virus risk factor, and presence or absence of pathogens showed no benefit of octreotide. Adverse events were more frequent in the octreotide-treated group. Conclusion: In the doses studied, octreotide was not more effective than placebo in patients with refractory AIDS-associated diarrhea. This lack of effectiveness may be attributable to inadequate sample size, doses, and duration of study treatment.",
author = "Simon, {Douglas M.} and Cello, {John P.} and Jorge Valenzuela and Richard Levy and Gordon Dickerson and Richard Goodgame and Michael Brown and Kip Lyche and Fessel, {W. Jeffrey} and James Grendell and Wilcox, {C. Mel} and Nezam Afdhal and Ronald Fogel and Vonda Reeves-Darby and John Stern and Owen Smith and Frank Graziano and Douglas Pleakow and Timothy Flanigan and Timothy Schubert and Mark Loveless and Larry Eron and Paul Basuk and Maurizio Bonacini and Jan Orenstein",
year = "1995",
doi = "10.1016/0016-5085(95)90137-X",
language = "English (US)",
volume = "108",
pages = "1753--1760",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea

AU - Simon, Douglas M.

AU - Cello, John P.

AU - Valenzuela, Jorge

AU - Levy, Richard

AU - Dickerson, Gordon

AU - Goodgame, Richard

AU - Brown, Michael

AU - Lyche, Kip

AU - Fessel, W. Jeffrey

AU - Grendell, James

AU - Wilcox, C. Mel

AU - Afdhal, Nezam

AU - Fogel, Ronald

AU - Reeves-Darby, Vonda

AU - Stern, John

AU - Smith, Owen

AU - Graziano, Frank

AU - Pleakow, Douglas

AU - Flanigan, Timothy

AU - Schubert, Timothy

AU - Loveless, Mark

AU - Eron, Larry

AU - Basuk, Paul

AU - Bonacini, Maurizio

AU - Orenstein, Jan

PY - 1995

Y1 - 1995

N2 - Background/Aims: Diarrhea is a significant problem in patients with acquired immunodeficiency syndrome (AIDS). The aim of this study was to determine octreotide effectiveness in refractory AIDS-associated diarrhea. Methods: In a 3-week protocol, 129 patients with a stool weight of >500 g/day despite standard antidiarrheal therapy were randomized to receive octreotide or placebo (3:2 ratio). Octreotide dose was increased 100 μg weekly to a maximum of 300 μg three times a day based on weekly 72-hour stool collections. Subsequently, patients received open-label octreotide at doses of up to 500 μg three times a day. Results: A 30% decrease in stool weight defined response. After 3 weeks, 48% of octreotide- and 39% of placebo-treated patients had responded (P = 0.43). At 300 μg three times a day, 50% of octreotide- and 30.1% of placebo-treated patients responded (P = 0.12). At a baseline stool weight of 1000-2000 g/day, 57% of octreotide- and 25% of placebo-treated patients responded (P = 0.06). Response rates based on CD4 counts, diarrhea duration, body weight, human immunodeficiency virus risk factor, and presence or absence of pathogens showed no benefit of octreotide. Adverse events were more frequent in the octreotide-treated group. Conclusion: In the doses studied, octreotide was not more effective than placebo in patients with refractory AIDS-associated diarrhea. This lack of effectiveness may be attributable to inadequate sample size, doses, and duration of study treatment.

AB - Background/Aims: Diarrhea is a significant problem in patients with acquired immunodeficiency syndrome (AIDS). The aim of this study was to determine octreotide effectiveness in refractory AIDS-associated diarrhea. Methods: In a 3-week protocol, 129 patients with a stool weight of >500 g/day despite standard antidiarrheal therapy were randomized to receive octreotide or placebo (3:2 ratio). Octreotide dose was increased 100 μg weekly to a maximum of 300 μg three times a day based on weekly 72-hour stool collections. Subsequently, patients received open-label octreotide at doses of up to 500 μg three times a day. Results: A 30% decrease in stool weight defined response. After 3 weeks, 48% of octreotide- and 39% of placebo-treated patients had responded (P = 0.43). At 300 μg three times a day, 50% of octreotide- and 30.1% of placebo-treated patients responded (P = 0.12). At a baseline stool weight of 1000-2000 g/day, 57% of octreotide- and 25% of placebo-treated patients responded (P = 0.06). Response rates based on CD4 counts, diarrhea duration, body weight, human immunodeficiency virus risk factor, and presence or absence of pathogens showed no benefit of octreotide. Adverse events were more frequent in the octreotide-treated group. Conclusion: In the doses studied, octreotide was not more effective than placebo in patients with refractory AIDS-associated diarrhea. This lack of effectiveness may be attributable to inadequate sample size, doses, and duration of study treatment.

UR - http://www.scopus.com/inward/record.url?scp=0029046946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029046946&partnerID=8YFLogxK

U2 - 10.1016/0016-5085(95)90137-X

DO - 10.1016/0016-5085(95)90137-X

M3 - Article

VL - 108

SP - 1753

EP - 1760

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 6

ER -